Trial · NCT01137682
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pasireotide LAR 40 mg | 65 | |
| Overall Study | STARTED | Pasireotide LAR 60 mg | 65 | |
| Overall Study | STARTED | Control Arm (Octreotide or Lanreotide) | 68 | |
| Overall Study | Not Treated | Pasireotide LAR 40 mg | 2 | |
| Overall Study | Not Treated | Pasireotide LAR 60 mg | 2 | |
| Overall Study | Not Treated | Control Arm (Octreotide or Lanreotide) | 1 | |
| Overall Study | Treated | Pasireotide LAR 40 mg | 63 | |
| Overall Study | Treated | Pasireotide LAR 60 mg | 63 | |
| Overall Study | Treated | Control Arm (Octreotide or Lanreotide) | 67 | |
| Overall Study | Completed 24-Week Core Phase | Pasireotide LAR 40 mg | 59 | |
| Overall Study | Completed 24-Week Core Phase | Pasireotide LAR 60 mg | 57 | |
| Overall Study | Completed 24-Week Core Phase | Control Arm (Octreotide or Lanreotide) | 65 | |
| Overall Study | Not Continuing Into Extension | Pasireotide LAR 40 mg | 2 | |
| Overall Study | Not Continuing Into Extension | Pasireotide LAR 60 mg | 3 | |
| Overall Study | Not Continuing Into Extension | Control Arm (Octreotide or Lanreotide) | 2 | |
| Overall Study | Continuing Into Extension | Pasireotide LAR 40 mg | 57 | |
| Overall Study | Continuing Into Extension | Pasireotide LAR 60 mg | 54 | |
| Overall Study | Continuing Into Extension | Control Arm (Octreotide or Lanreotide) | 63 | |
| Overall Study | Safety Set - CORE | Pasireotide LAR 40 mg | 63 | |
| Overall Study | Safety Set - CORE | Pasireotide LAR 60 mg | 62 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01137682/flow